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Abstract 
 
Introduction: Recently, tyrosine kinase inhibitors (TKIs) have emerged as a new class of anti-cancer 
therapy. Although generally considered less toxic than cytotoxic chemotherapy, TKIs do have 
significant side effects including fatigue and hypertension. In addition, thyroid dysfunction is a well-
known adverse effect of TKI.  
Areas covered: This review provides a comprehensive assessment of TKI-induced thyroid 
dysfunctions, induced by sunitinib, sorafenib, vandetanib, motesanib, axitinib, etc. Furthermore, the 
potential mechanisms that result in this toxicity, the clinical meaning of thyroid dysfunction in these 
patients, and controversies regarding treatment with thyroid hormone therapy, will be evaluated. 
Expert Opinion: Detection of TKI-induced thyroid dysfunction requires routine monitoring of thyroid 
function and may necessitate treatment. Potential benefits to developing thyroid dysfunction and 
potential harm in treating it necessitate controlled studies. Finally, if treatment is pursued, appropriate 
dosing and timing of thyroid hormone replacement will require prospective clinical evaluation. 
 
Keywords: axitinib, hyperthyroidism, hypothyroidism, imatinib, sorafenib, sunitinib, thyroid cancer, 
thyroid dysfunctions, tyrosine kinase inhibitors, vandetanib. 
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1. Introduction 
 
Recently, tyrosine kinase inhibitors (TKIs) have emerged as a new class of anti-cancer therapy. Due to 
increased knowledge of the molecular pathogenesis of cancer, therapeutic agents that target specific 
altered pathways [RET, BRAF, RAS, epidermal growth factor receptor (EGFR), vascular endothelial 
growth factor (VEGF) receptor (VEGFR), etc] have been developed [1]. TKIs are small compounds 
that affect tyrosine kinase-dependent oncogenic pathways by competing with ATP-binding sites of the 
tyrosine kinase (TK) catalytic domains [2]. Occupation of these sites inhibits autophosphorylation and 
activation of the TKs and prevents the further activation of intracellular signaling pathways. TKIs can 
be specific to one or several homologous TKs [3]. Several multitargeted TKIs have demonstrated 
significant clinical activity including sunitinib, sorafenib, etc. [4-6]. The inhibition of only one kinase 
receptor may induce the compensatory activation of other TKs and consequent resistance to treatment 
with TKIs [7]. Therefore, the simultaneous inhibition of multiple activated TKs may be the best way to 
approach cancer [8]. Several multitarget TKIs are now approved by the US Food and Drug 
Administration, EMA, etc. Sunitinib and sorafenib are approved for advanced renal cell carcinoma 
(RCC) [9,10]. In addition, sunitinib has also been approved for gastrointestinal stromal tumor (GIST) 
and pancreatic neuroendocrine tumors, whereas sorafenib is approved for hepatocellular carcinoma 
(HCC) [11,12]. In aggressive medullary thyroid cancer (MTC) new TKIs have been approved such as 
vandetanib, or cabozantinib [13], while in dedifferentiated follicular thyroid cancer sorafenib, and other 
new TKIs, have been evaluated [14-17]. TKIs are only one of the several drugs that interfere with 
thyroid homeostasis [18]. 
Although generally considered less toxic than cytotoxic chemotherapy, TKIs do have significant side 
effects including fatigue and hypertension [19,20]. 
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In addition, thyroid dysfunction is a well-known adverse effect of TKI [21]. Detection of TKI-induced 
thyroid dysfunction requires routine monitoring of thyroid function and may require treatment. This 
review provides a comprehensive assessment of TKI-induced thyroid dysfunctions, induced by 
sunitinib, sorafenib, vandetanib, motesanib, axitinib, etc. Furthermore, the potential mechanisms that 
result in this toxicity, the clinical meaning of thyroid dysfunction in these patients, and controversies 
regarding treatment with thyroid hormone (TH) therapy, will be evaluated. 
 
2. Hypothyroidism 
 
The most frequent thyroid dysfunction induced by TKIs is hypothyroidism. A number of TKIs were 
reported to cause hypothyroidism (Table 1). 
2.1 Sunitinib 
Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase that inihibits platelet-
derived growth factor receptors (PDGFRs) and VEGFRs, and plays a role in both tumor angiogenesis 
and tumor cell proliferation. Sunitinib is used in the treatment of metastatic RCC (mRCC) and 
imatinib-resistant metastatic gastrointestinal tumors. It is administered in a four-weeks-on, two-weeks-
off cycle. Hypothyroidism is frequently observed with sunitinib, with a reported incidence of 53% to 
85% in retrospective studies and 36% to 46% incidence in prospective studies [22-31]. 
An incidence analysis was performed using 6678 sunitinib-treated patients from all 24 eligible trials. 
The incidence of all- and high-grade hypothyroidism was 9.8% (95% CI 7.3–12.4%) and 0.4% (95% 
CI 0.3–0.5%), respectively. A meta-analysis of seven randomized trials with 2787 subjects revealed a 
relative risk (RR) of all- and high-grade hypothyroidism of 13.95 (95% CI 6.91–28.15; p<0.00001) and 
4.78 (95% CI 1.09–20.84; p=0.04), respectively. Subgroup analysis revealed a significantly higher 
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incidence of all-grade hypothyroidism in patients receiving sunitinib for longer duration than in 
patients receiving sunitinib for shorter duration [27]. 
Several potential mechanisms of sunitinib induced thyroid hypothyroidism have been proposed. The 
high incidence of transient thyrotoxicosis prior to developing hypothyroidism suggested destructive 
thyroiditis [32]. However, other studies have shown recovery of thyroid stimulating hormone (TSH) 
values to the normal range following treatment with sunitinib [25,33]. Clinical studies of thyroid 
radioiodine uptake inhibition suggested an inhibition of iodide uptake [24], but in vitro studies showed 
no impairment of iodide uptake [34]. In vitro [23] it has been shown that sunitinib impairs peroxidase 
activity, but this has not yet been confirmed in vivo. Since sunitinib inhibits VEGFRs as a principal 
mechanism of its action on tumors, regression of the thyroid vascular bed induced by VEGF inhibition 
is the likely explanation. Mouse studies have shown glandular capillary regression with sunitinib 
exposure [35], suggesting that sunitinib inhibits VEGFRs inducing the regression of the thyroid 
vascular bed. It has been reported that thyroid volume and blood flow were both reduced on sunitinib 
[36]. However, another study did not detect changes in thyroid volume with ultrasonography or 
vascularity with echo-color Doppler between before and during sunitinib treatment [24]. It has also 
been shown that sunitinib inhibited TH transport mediated by the transmembrane transporter MCT8 
[37]. Further studies are needed to finally elucidate the mechanism of sunitinib induced hypothyroidism. 
2.2 Sorafenib 
Sorafenib targets multiple kinases including BRAF, VEGFR, and RET and is approved for the 
treatment of advanced RCC and advanced HCC in addition to being evaluated in other tumors 
including lung, pancreatic, prostate, and differentiated thyroid cancer [15,38]. Incidence of thyroid 
dysfunction with sorafenib was much less when compared to sunitinib, ranging between 20 and 36% as 
evaluated in different studies [28-30]. A retrospective study of 39 patients treated with sorafenib [28] 
identified thyroid dysfunction attributable to the drug in 21% of patients. A prospective study in a 
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cohort of patients [39] suggested that hypothyroidism may occur more frequently in Japanese than in 
Western patients. Sorafenib-induced hypothyroidism can persist after withdrawal of treatment [40]. In a 
study designed to determine incidence rates of TH therapy as a surrogate for sorafenib-induced clinical 
hypothyroidism, 77 of 1214 sorafenib patients (6.3%) received a TH [41].  
The mechanism by which sorafenib induces hypothyroidism is not yet well understood. The 
relationship between thyroid size (measured by computed tomography) and thyroid function in patients 
with RCC receiving sorafenib has been evaluated. The patients who developed "hypothyroidism", after 
sorafenib showed thyroid size reduction of 79 ± 13%, after 12 months [42]. In a study of 21 patients 
treated with sorafenib, serum free thyroxine (T4) and triiodothyronine (T3) levels, adjusted for 
levothyroxine (L-T4) dose per kilogram body weight, decreased by 11 and 18%, respectively, whereas 
TSH levels increased. The serum T3/T4 and T3/reverse T3 ratios decreased by 18 and 22%, 
respectively, which is compatible with increased type 3 deiodination [43]. 
2.3 Pazopanib  
Pazopanib is a potent and selective multi-targeted receptor TKI (targeting VEGFR 1, 2, and 3, c-kit, 
and PDGFR) that blocks tumor growth and inhibits angiogenesis [44].  
It has been approved for RCC and soft tissue sarcoma [45]. 
A review of the literature [46] identified thyroid dysfunction attributable to pazopanib with an 
incidence of 7% in patients treated for mRCC. The incidence and severity of thyroid dysfunction were 
explored in 578 pazopanib-treated patients participating in 3 trials, and it was found that 37 patients 
(6%) had elevated TSH at baseline (>5 mU/L), 167 (29%) had a TSH value of >5 mU/L during 
treatment. Hypothyroidism (TSH > 5– 10 mU/L, and T4 < lower normal limit) was also observed in 19 
(3%) patients [47]. A randomized, double-blind, placebo-controlled Phase III study evaluated efficacy 
and safety of pazopanib monotherapy in treatment-naive and cytokine-pretreated patients with 
advanced RCC. It was found that the incidence of hypothyroidism was less than 10% [48]. A Phase III, 
 7 
randomized trial compared the efficacy and safety of pazopanib vs sunitinib as first-line therapy. The 
prevalence of hypothyroidism in pazopanib treated patients was 12% [49]. In a retrospective study of 
patients with mRCC who received pazopanib hypothyroidism was observed in 18% [50]. 
2.4 Imatinib 
Imatinib is an oral TKI with activity against RET, BCR-ABL, PDGFR, c-Fms and c-Kit. Imatinib is 
approved for the treatment of chronic myeloid leukemia (CML), GIST, and dermatofibrosarcoma 
protuberans and is being evaluated for other tumors including MTC. In a study of 11 patients (1 GIST, 
10 MTC) who received imatinib, eight (who had previously undergone thyroidectomies and were on 
TH therapy) needed increased TH requirements while on imatinib treatment [31,51]. In another study 9 
out of 15 patients with advanced MTC who received imatinib (who previously underwent total 
thyroidectomy) and were on TH replacement, needed increased TH requirements while on therapy. On 
the other hand, patients with intact thyroid glands remained euthyroid while on imatinib [52]. These 
studies suggest that imatinib-induced thyroid dysfunction is not due action on the thyroid gland itself. 
This finding was further illustrated in a study of 68 patients with CML who received imatinib [53]. All 
patients had intact thyroid glands; there were no observed cases of thyroid dysfunction. A case of a 59-
year-old woman who was under L-T4 therapy for hypothyroidism secondary to subtotal thyroidectomy, 
with clinical and biochemical euthyroidism, who required an increased dose of L-T4 after starting 
imatinib therapy, confirmed the above mentioned concept [54]. 
However in another study thyroid dysfunction in Philadelphia (Ph) chromosome-positive CML patients 
under treatment with imatinib were detected in 25% [55]. 
2.5 Dasatinib 
Dasatinib is a second-generation TKI with activity against BCR-ABL and sarcoma that is approved for 
the treatment of imatinib-resistant Ph-positive CML and Ph-positive acute lymphoblastic leukemia. 
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Thyroid function was retrospectively reviewed in ten patients who received dasatinib, 5 (50%) 
developed hypothyroidism (4 subclinical, 1 clinical), none required treatment [55]. 
2.6 Nilotinib 
Nilotinib is a small molecule TKI approved for the treatment of imatinib-resistant Ph-positive CML. 
The effect of nilotinib on thyroid function tests in patients with Ph-positive CML was studied. Of 55 
patients, twelve patients (22%) had thyroid function tests consistent with hypothyroidism (6 subclinical, 
6 clinical) at some point during their therapy. Six (11%) patients were on thyroid medication before to 
starting the nilotinib therapy and did not require a change in their L-T4 dose. Eighteen (33%) patients 
had received interferon previously, the development of thyroid dysfunction was slightly more common 
in these patients although not statistically significant, suggesting that interferon is not related to the 
appearance of thyroid dysfunctions. Three patients treated with nilotinib had positive anti-thyroid 
antibodies, with an episode of hyperthyroidism preceding the development of hypothyroidism. 
Hypothyroidism resolved spontaneously in three of these patients [55].  
More recently the case of a 76-year-old man with chronic-phase CML who suffered from severe 
systemic edema after introduction of nilotinib has been reported. Laboratory tests revealed 
hypothyroidism; the patient was euthyroid prior to introduction of nilotinib. Serum TSH was 30 µU/mL 
with low free T4 and free T3, confirming overt hypothyroidism; anti-thyroid antibodies were negative. 
Ultrasound examination showed a normal size gland, markedly decreased dyshomogeneous 
echotexture and slightly reduced vascularity, all compatible with thyroiditis. His edema regressed 
dramatically after TH replacement therapy, while continued treatment with nilotinib, and laboratory 
examination of thyroid function also improved markedly [56]. 
The mechanism by which nilotinib induces hypothyroidism remain to be investigated. In an attempt to 
test whether inhibition by TKIs of renal tubular MCT8 increases urinary T4 excretion, T4 in urine from 
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11 patients treated with imatinib, dasatinib, or nilotinib was determined. T4 excretion was not increased 
compared with untreated patients [37]. 
2.7 Vandetanib 
Vandetanib is an anti-cancer drug that is approved for the treatment of MTC. It acts as a kinase 
inhibitor of a number of cell receptors, mainly VEGFR, EGFR, and the RET-tyrosine kinase [57-59]. 
Thyroid function was studied in 19 patients treated with vandetanib (100 mg) for locally advanced or 
metastatic hereditary MTC. All 19 patients receiving vandetanib in this study had undergone prior 
thyroidectomy and were receiving TH replacement before entering study. Baseline TSH data were 
available for 17 patients, and in these patients an increase in TSH levels was observed [5.1-fold (mean) 
and 7.3-fold (median) increases over baseline]. No patients were reported to have symptomatic 
hypothyroidism, but TH replacement therapy was increased in two patients [60]. 
2.8 Axitinib 
Axitinib is a small molecule TKI that has been successful in clinical trials with RCC. It has received 
approval for use as a treatment for RCC [61]. Axitinib is investigated also in lung cancer, and other 
solid tumors [62]. 
Thyroid function was studied in 18 Japanese patients with advanced solid tumors in two Phase I trials 
that evaluated the safety, pharmacokinetics and antitumor activity of axitinib. Sixteen patients (89%) 
experienced TSH elevation. Grade 3/4 toxicities included fatigue (28%). No grade 3/4 fatigue occurred 
in patients who started TH replacement therapy when TSH was elevated. Thyroglobulin elevation was 
observed in all patients who continued treatment with axitinib for ≥ 3 months. Abnormal TSH 
correlated with exposure to axitinib [63]. 
In a further study, at baseline, a similar percentage of Japanese patients in the axitinib and sorafenib 
arms were receiving medications such as L-T4 for hypothyroidism (12 and 14%, respectively). 
However, during study treatment, more patients administered with axitinib were diagnosed with 
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hypothyroidism than those receiving sorafenib (44 and 24%, respectively). The diagnosis of 
hypothyroidism in either arm was more common among Japanese than in the overall population. 
Hypothyroidism was managed with TH replacement therapy as the protocol recommended that 
hypothyroidism be treated per standard medical practice to maintain euthyroid state. In the Japanese 
subgroup, 12% of patients received thyroid medications before starting treatment with axitinib and 48% 
of patients started thyroid medications or increased the dose of existing thyroid medications during 
treatment with axitinib. In the overall population, the corresponding values were 19 and 26%, 
respectively [64]. In another Phase III trial comparing axitinib with sorafenib in patients with 
treatment-naive mRCC, hypothyroidism was more common in axitinib treated patients (39 [21%] vs 7 
[7%]) [65]. A further study reported a high prevalence of hypothyroidism in a Phase II trial of 
neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell RCC [66]. 
2.9 Motesanib 
Motesanib is an orally administered small molecule belonging to angiokinase inhibitor class which acts 
as an antagonist of VEGFRs, PDGFRs, and stem cell factor receptors. In 2011, it was reported that a 
Phase III trial did not show benefit for advanced non-squamous non-small-cell lung carcinoma [67]. 
The drug is separately undergoing Phase II evaluation as first-line therapy for breast cancer [68]. There 
have also been clinical trials for thyroid cancer [69]. 
In an open-label, single-group, Phase II study, 93 patients (who had progressive, locally advanced or 
metastatic, radioiodine-resistant differentiated thyroid cancer) were treated with 125 mg of motesanib 
diphosphate, administered orally once daily. All the patients had previously undergone thyroidectomies 
and were on TH replacement. Increased serum TSH concentrations, hypothyroidism or both were 
observed in 20 patients (22%). The authors suggested that alterations in the absorption or metabolism 
of L-T4 may explain changes in TH levels while on motesanib [70]. 
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A Phase II study investigated the efficacy and tolerability of motesanib, in advanced MTC. Of 91 
enrolled patients who received motesanib hypothyroidism was observed in 29% [71]. 
2.10 Tivozanib 
Tivozanib blocks the activation of VEGFR 1, 2, and 3 more potently than earlier TKIs. In a Phase III 
study of tivozanib vs sorafenib as initial targeted therapy for patients with mRCC, incidence of 
hypothyroidism was higher in the tivozanib arm than in the sorafenib arm. TSH levels that were normal 
prior to dosing but increased to > 10 mU/L during treatment were reported for 30.1% of tivozanib 
subjects vs 7.0% of the patients who received sorafenib. A smaller number of tivozanib subjects had 
low free T3 or free T4 on or after the date that the elevations of TSH were observed (8.9% with low 
T3; 1.9% with low free T4), consistent with the occurrence of hypothyroidism adverse events. It is 
important that the incidence of hypothyroidism for sorafenib reported in this Phase III trial was lower 
as compared to that in earlier studies [72]. Also, in a Phase I study of tivozanib, in Japanese patients 
with solid tumors, among 9 patients treated, 2 reported hypothyroidism (22%) [73]. 
 
3. Hyperthyroidism 
 
Hyperthyroidism is observed with a lower prevalence in patients treated with TKIs. A number of TKIs 
were reported to cause hyperthyroidism (Table 2). 
3.1 Sunitinib 
In a prospective observational cohort study that included patients with normal baseline TSH, observed 
while on sunitinib, for thyroid dysfunction, for a median period of 37 weeks, it was found 40% had 
suppressed TSH prior to the appearance of hypothyroidism, suggesting that thyroiditis could have been 
the possible mechanism for the subsequent development of hypothyroidism [32]. This hypothesis was 
confirmed by the case report of a patient with transient overt thyrotoxicosis followed by 
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hypothyroidism, apparently related to sunitinib therapy [74]. A series of six patients who developed 
thyrotoxicosis while on sunitinib for mRCC was described. Two patients developed severe 
thyrotoxicosis within 10 weeks after commencing sunitinib. In contrast, in the four patients who 
presented with later onset (16-30 weeks) thyrotoxicosis, the thyrotoxicosis was relatively mild, self-
limiting and rapidly progressed to hypothyroidism. These patients experienced recurrent episodes of 
thyrotoxicosis in temporal relation to their cyclical sunitinib treatment. These findings reinforced the 
hypothesis that sunitinib-induced hypothyroidism may be a consequence of preceding thyroiditis with 
associated transient thyrotoxicosis [33]. A total of 24 patients treated by sunitinib for RCC were studied 
for thyroid function; TSH levels were below the normal range in five patients (20.8%) before or during 
the treatment period, suggesting the diagnosis of subclinical hyperthyroidism [75]. In seven cases, 
during sunitinib treatment for advanced mRCC, mild hypothyroidism developed early in the first 
treatment cycle, and recovered spontaneously. Transient hyperthyroidism was observed during the 
second or third treatment cycles and was preceded by a rapid increase in thyroglobulin levels. (99m)Tc 
scintigraphy in the hyperthyroid state showed decreased thyroidal uptake of (99m)TcO(4)(-), 
suggesting destructive thyroiditis. Hypothyroidism subsequently developed, requiring L-T4 
replacement therapy. Ultrasonography showed a hypoechogenic pattern of the parenchyma and 
decreased intrathyroidal blood flow. The thyroid glands ultimately became atrophic, which may 
progress to permanent hypothyroidism. These findings suggest that sunitinib-induced hypothyroidism 
may occur frequently and may be a consequence of thyroiditis with transient thyrotoxicosis [76]. 
Another case report showed a patient with RCC who developed transient overt thyrotoxicosis followed 
by hypothyroidism due to sunitinib treatment [77]. Four patients developed hyperthyroidism after the 
treatments with sunitinib. Their hyperthyroidism was diagnosed as destructive thyroiditis-induced 
thyrotoxicosis based on the clinical course (thyroid functions subsequently became normal without any 
treatment in all patients) and/or negative thyroid receptor antibodies measured in a patient. Of the four 
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patients who developed hyperthyroidism after treatment with sunitinib, three had hypothyroidism 
before the treatment [78]. The above mentioned studies suggest that hyperthyroidism may be related to 
destructive thyroiditis in the course of sunitinib treatment, and it is frequently followed by 
hypothyroidism. 
3.2 Sorafenib 
Among sixty-eight patients with mRCC treated with sorafenib, 39 patients had thyroid function tests 
available, eight patients (21%) had thyroid dysfunction possibly caused by sorafenib [seven 
hypothyroidism (18%) and one hyperthyroidism (3%)] [28]. 
Another study reported two patients who developed temporary hyperthyroidism during the course of 
sorafenib treatment for HCC, which was followed by overt and subclinical hypothyroidism, 
respectively. Thyroid ultrasonography showed an atrophic thyroid gland in patient 1, and signs of 
thyroiditis in patient 2. Detailed reassessment of thyroid volumes on routinely performed CT scans 
showed a gradual decrease in thyroid volume during sorafenib treatment in one patient, suggesting 
progressive thyroid destruction [79]. Another case report describes hyperthyroidism and thyroid 
autoimmunity induced by sorafenib in mRCC [80]. A case of sorafenib induced thyroid storm has been 
also reported [81]. 
The above mentioned studies suggest that hyperthyroidism may be related to destructive thyroiditis in 
the course of sorafenib treatment, and it is frequently followed by hypothyroidism. Only rarely 
hyperthyroidism induced by sorafenib needs to be treated. 
3.3 Axitinib 
Among six patients treated with axitinib for mRCC transient thyrotoxicosis due to destructive 
thyroiditis occurred in five patients within 7 months of treatment. Four patients exhibited both hyper-
and hypothyroidism [82]. 
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4. Clinical impact of TKI induced thyroid dysfunction 
 
Many data suggest TKI induced thyroid dysfunction may have a prognostic value. Wolter et al. 
prospectively evaluated thyroid function in patients receiving sunitinib for advanced RCC [83]. The 
median progression-free survival (PFS) was 3.6 months when thyroid function tests remained within 
normal limits and 10.3 months when abnormal thyroid function tests were noted. The median overall 
survival was 6.6 months in patients with normal thyroid function tests and 18.2 months in patients with 
abnormal thyroid function tests [83]. In a Japanese study of 14 patients with mRCC who were treated 
with sunitinib, the tumor response rate was 73% (8/11) in patients with hypothyroidism and 33% (1/3) 
in patients who remained euthyroid [84]. A prospective analysis of 87 patients with mRCC who 
received treatment with sunitinib or sorafenib [30] confirmed the above mentioned data. Subclinical 
hypothyroidism was present in five patients at baseline and was diagnosed in 30 patients (36.1%) 
within the first 2 months of therapy. Patients with subclinical hypothyroidism had a statistically 
significant objective remission rate of 28.3% vs 3.3% in euthyroid patients and increase of median 
duration of survival [30]. Another study evaluated patients with mRCC who received sunitinib or 
sorafenib [31]. Twenty-one of 66 evaluable patients (31.8%) developed hypothyroidism. 
Hypothyroidism was associated with a longer PFS (16.0 +/− 0.8 months vs 6.0 +/− 0.8 months, p = 
0.032). Hypothyroidism was found to be an independent prognostic predictor of survival in 
multivariate analysis [31]. Among thirty-one consecutive patients with clear cell mRCC treated with 
sunitinib, hypothyroidism occurred in 16 patients (52%) within 3 months (range 0.7-22.9) of treatment 
initiation. Thyroid replacement corrected TSH below the upper normal limit in 10 patients (63%). The 
hypothyroid patients tended to have longer PFS (median 12.2 vs 9.4 months; p = 0.234) and longer 
survival (median 22.4 vs 13.9 months; p = 0.234) than the euthyroid patients [85].   
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The observed correlation between the development of hypothyroidism and improved survival with TKI 
therapy may suggest a potential relationship between hypothyroidism and decreased cancer growth.  
It might be speculated that cancer growth decreases because of reduced TKI metabolism and 
subsequent drug accumulation in patients with hypothyroidism. 
It has been also suggested that patients developing thyroid dysfunction might tend to have their cancer 
better controlled through the common antiangiogenic effects affecting both the tumor and the thyroid 
[21]. The above mentioned studies suggest a correlation between the development of hypothyroidism 
and a better prognosis, but several questions are still unanswered, such as whether the time course to 
hypothyroidism would predict response to cancer therapy, and whether developing hypothyroidism 
soon after therapy or later on would affect clinical response. 
 
5. Treatment of tyrosine kinase inhibitors associated thyroid dysfunction 
 
There are still no guidelines regarding the frequency of thyroid function tests monitoring and treatment 
of thyroid dysfunctions induced by TKIs. As a reasonable guideline, the determination of serum TSH 
concentration on day 1 of each cycle has been suggested, but this has not been proven [84]. Wolter et al. 
proposed measuring TSH on days 1 and 28 of the first 4 cycles of sunitinib because most thyroid 
function tests abnormalities were noted to occur in the first cycles. Moreover, he suggested that patients 
with normal TSH values after the first 4 cycles can have their TSH measured on day 28 of every 3rd 
cycle [25]. Patients with preexisting thyroid abnormalities, on TH replacement, may need increased 
requirements [40,86]. About the level of TSH elevation that warrants treatment, the American Thyroid 
Association, the American Association of Clinical Endocrinologists, and the Endocrine Society 
recommend TH to be initiated when TSH rises to a level above 10 µU/mL, but data is lacking with 
regard to treatment of TSH between 4.0 and 10. Wolter et al. recommended TH replacement if 
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circulating TSH exceeded 10 µU/mL on day 1 of a cycle of sunitinib therapy, and he warned against 
TH replacement based on results of thyroid function tests on day 28, since this may lead to 
overtreatment at the end of treatment [25]. In addition, Garfield et al. cautioned against the routine use 
of TH replacement, as it could induce tumor growth in patients with active cancers, in fact, it has been 
suggested that hypothyroidism in these patients was protective [87]. 
However, a study by Bladou et al. compared PFS in patients treated for thyroid dysfunction developing 
with sunitinib therapy with respect to those not treated. The authors noted that PFS was not different 
between the two groups (p = 0.94). Therefore, the relationship between exogenous TH and cancer 
growth is still not yet established. Other trials are needed to further investigate whether TH replacement 
would affect cancer outcomes [88]. 
 
6. Conclusion 
 
TKIs belong to a new class of molecular multitargeted anticancer therapy which targets different 
growth factor receptors (RET, BRAF, RAS, EGFR, VEGFR, etc). They are currently used for 
treatment of aggressive RCC, HCC and GIST tumors, thyroid cancer, etc. A number of reports have 
demonstrated that TKIs can induce hypothyroidism, which was especially more common with sunitinib, 
sorafenib, axitinib, and vandetanib (Table 3). Hyperthyroidism, mainly subclinical and transitory, has 
been reported also with sunitinib, sorafenib and axitinib. Many mechanisms have been proposed to 
explain the induction of thyroid dysfunction, including the induction of thyroiditis, capillary regression 
in the thyroid gland, antithyroid peroxidase antibody production, and their ability to decrease iodine 
uptake by the thyroid gland. Clinical studies suggest that TKI-induced thyroid dysfunction may be 
protective as it was shown to improve overall survival. Follow-up on thyroid function tests in patients 
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treated with TKIs is recommended. When thyroid dysfunction occurs, appropriate treatment depends 
on patients symptoms and hormonal evaluation. 
 
7. Expert Opinion 
 
TKIs belong to a new class of molecular multitargeted anticancer therapy which targets different 
growth factor receptors (RET, BRAF, RAS, EGFR, VEGFR, etc). They are currently used for 
treatment of aggressive RCC, HCC and GIST tumors, thyroid cancer, etc. A number of reports have 
demonstrated that TKIs can induce thyroid dysfunctions. A number of reports have demonstrated that 
TKIs can induce hypothyroidism. Hypothyroidism is frequently observed with sunitinib, with a 
reported incidence of 53% to 85% in retrospective studies and 36% to 46% incidence in prospective 
studies. Incidence of thyroid dysfunction with sorafenib was much less when compared to sunitinib, 
ranging between 20 and 36% as evaluated in different studies; also for sorafenib the most frequently 
reported thyroid dysfunction was hypothyroidism. Imatinib has been shown to cause increased TH 
requirements in patients after thyroidectomy; while patients with intact thyroid glands remained 
euthyroid while on imatinib. Also for vandetanib an increase in TSH levels was observed in patients 
after thyroidectomy receiving TH replacement. Hypothyroidism in axitinib treated patients is about 
20%. Hypothyroidism has been also reported in association with the treatments with pazopanib, 
motesanib, nilotinib or tivozanib. Detection of TKI-induced thyroid dysfunctions requires routine 
monitoring of thyroid function and may necessitate treatment. Serum TSH concentration on day 1 of 
each cycle has been suggested as a reasonable guideline to detect thyroid dysfunctions. Patients with 
preexisting thyroid abnormalities, on TH replacement, may need increased TH requirements. About the 
level of TSH elevation that warrants treatment, the American Thyroid Association, the American 
Association of Clinical Endocrinologists, and the Endocrine Society recommend TH to be initiated 
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when TSH rises to a level above 10 µU/mL, but data is lacking with regard to treatment of TSH 
between 4.0 and 10 µU/mL. Some studies cautioned against the routine use of TH replacement, as it 
could induce tumor growth in patients with active cancers other than thyroid cancer, in fact, it has been 
suggested that hypothyroidism in these patients was protective. Hyperthyroidism has been reported also 
with sunitinib, sorafenib and axitinib, but it is mainly subclinical and transitory. In prospective 
observational cohort studies that included patients with normal baseline TSH, observed while on 
sunitinib, for thyroid dysfunction, it was found 40% had suppressed TSH prior to the appearance of 
hypothyroidism, suggesting that thyroiditis could have been the possible mechanism for the subsequent 
development of hypothyroidism. It has been also shown that during sorafenib treatment 
hyperthyroidism may be related to destructive thyroiditis, and it is frequently followed by 
hypothyroidism. Only rarely hyperthyroidism induced by sorafenib needs to be treated. Several 
potential mechanisms of TKIs induced thyroid dysfunctions have been proposed. The high incidence of 
transient thyrotoxicosis prior to developing hypothyroidism suggested destructive thyroiditis. However, 
other studies have shown thyroid radioiodine uptake inhibition, impairment of peroxidase activity, 
regression of the thyroid vascular, or inhibition of thyroid hormone transport mediated by the 
transmembrane transporter MCT8, by TKIs. Further studies are needed to finally elucidate the 
mechanism of TKIs induced dysfunctions. 
Potential benefits to developing thyroid dysfunctions and potential harm in treating it necessitate 
controlled studies. Finally, if treatment is pursued, appropriate dosing and timing of thyroid hormone 
replacement would require prospective clinical evaluation. 
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Article Highlights Box 
 
1. TKIs do have significant side effects including fatigue and hypertension; in particular thyroid 
dysfunction is a well-known adverse effect of TKIs. 
2. The most frequent thyroid dysfunction induced by TKIs is hypothyroidism.  
3. It is recommended TH to be initiated when TSH rises above 10 µU/mL, but data is lacking with 
regard to treatment of TSH levels between 4.0 and 10. 
4. Hyperthyroidism is frequently related to destructive thyroiditis, and followed by hypothyroidism. 
5. Follow-up on thyroid function tests in patients treated with TKIs is recommended. TSH 
concentrations on day 1 of each cycle has been suggested. 
6. When thyroid dysfunction occurs, appropriate treatment depends on the patient’s individual 
symptoms and hormonal evaluation. 
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Table 1. Prevalence of hypothyroidism in patients treated with different tyrosine kinase 
inhibitors. 
 
Drug Prevalence Range 
Sunitinib 36-85% 
Sorafenib 18-36.1% 
Pazopanib 3-18% 
Imatinib 25% 
Dasatinib 50% 
Nilotinib 22% 
Vandetanib 89.47% 
Axitinib 12-89% 
Motesanib 22-29% 
Tivozanib 22-30.1% 
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Table 2. Prevalence of hyperthyroidism for different tyrosine kinase inhibitors used. 
 
Drug Prevalence Range 
Sunitinib 19-40% 
Sorafenib 3% 
Axitinib 67% 
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Table 3. Drugs, relative molecular targets, and thyroid disorders related to each one. 
 
Agent Molecular targets Reported thyroid disorders 
Sunitinib 
VEGFR-2, 
PDGFR, 
c-KIT, 
RET, 
CSF-1R, 
FLT3 
Hypothyroidism 
 
Transient thyrotoxicosis prior to 
developing hypothyroidism 
 
Subclinical hyperthyroidism 
 
Transient hyperthyroidism 
 
Sorafenib 
RAF, 
VEGFR-1 
and -2, 
RET, 
PDGFR, 
c-KIT 
Hypothyroidism 
 
Temporary hyperthyroidism 
 
Hyperthyroidism 
Pazopanib 
VEGFR-1, 
-2, -3, 
PDGFR, 
c-KIT 
Hypothyroidism 
 
Imatinib 
Bcr-abl, 
RET, 
PDGFR, 
c-KIT 
Hypothyroidism 
 
Dasatinib 
BCR/Abl, 
Src, c-Kit, 
ephrin 
receptors, 
Hypothyroidism 
 
Nilotinib 
BCR/Abl,
KIT, 
LCK, 
EPHA3, 
EPHA8, 
DDR1, 
DDR2, 
PDGFRB, 
MAPK11,
ZAK 
Hypothyroidism 
 
Thyroiditis 
 
Vandetanib 
VEGFR-2, 
VEGFR-3, 
RET, 
EGFR 
Hypothyroidism 
 
Axitinib VEGFR-1, Hypothyroidism 
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-2, and -3, 
PDGFR, 
c-KIT 
 
Transient thyrotoxicosis 
 
Hyperthyroidism 
 
Motesanib 
VEGFR-1, 
-2, -3, 
PDGFR, 
c-KIT 
Hypothyroidism 
 
Tivozanib VEGFR-1, -2, -3 
Hypothyroidism 
 
 
 
 
